(S)-2-甲基丁醇乙酸酯 | 6493-92-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-甲基丁醇乙酸酯
• 英文名称: (S)-2-methyl-1-butyl acetate
• 英文别名: (S)-1-acetoxy-2-methyl-butane；(S)-2-Methylbutyl acetate；[(2S)-2-methylbutyl] acetate
• CAS: 6493-92-1
• 化学式: C₇H₁₄O₂
• 分子量: 130.187
• InChiKey: XHIUFYZDQBSEMF-LURJTMIESA-N

物化性质

• 沸点：
  135 °C
• 密度：
  0.879
• 闪点：
  35 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  S-(-)-2-甲基-1-丁醇 、 乙酸酐 、 吡啶 生成 (S)-2-甲基丁醇乙酸酯
  参考文献：
  名称：

  NAHRSTEDT, ADOLF;ECONOMOU, DIMITRIOS;WRAY, VICTOR, J. NATUR. PROD., 53,(1990) N, C. 1387-1389

  摘要：

  DOI：

文献信息

• [EN] NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO<br/>[FR] NOUVEAUX COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS CORRESPONDANTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010149684A1

  公开（公告）日：2010-12-29

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R1, R2, R3, n, p, q, and Ar are as defined herein, including stereoisomers, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明公开了具有结构(I)的新化合物，其在患者中治疗各种与代谢相关的病症具有实用性：其中R1、R2、R3、n、p、q和Ar如本文所定义，包括立体异构体、溶剂合物和药学上可接受的盐。还公开了包含本发明化合物的药物组合物，以及关于其在有需要的患者中使用的方法。
• SUBSTITUTED IMIDAZOLES
  申请人：CHUBB NATHAN ANTHONY LOGAN

  公开号：US20070167506A1

  公开（公告）日：2007-07-19

  This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.

  本发明涉及一系列α取代的2-苄基取代咪唑化合物及其药用可接受盐和溶剂化合物，包括这些化合物的组合物、合成过程以及它们作为驱虫剂的用途。
• Electrophysiological and Behavioral Activity of Secondary Metabolites in the Confused Flour Beetle, Tribolium confusum
  作者：F. Verheggen、C. Ryne、P.-O. C. Olsson、L. Arnaud、G. Lognay、H.-E. Högberg、D. Persson、E. Haubruge、C. Löfstedt

  DOI：10.1007/s10886-006-9236-3

  日期：2007.2.15

  Several previous studies have addressed pheromone communication in various flour beetles (Coleoptera: Tenebrionidae), including the confused flour beetle, Tribolium confusum (du Val). Different stereoisomers of 4,8-dimethyldecanal (DMD) were reported as the only components of an aggregation pheromone, but the behavioral activity of DMD is low. In the present study, additional previously reported secondary

  先前的一些研究已经解决了各种甲虫（鞘翅目：天牛科）中的信息素交流，包括混淆的甲虫Tribolium confusum（杜瓦尔）。据报道，不同的立体异构体的4,8-二甲基癸醛（DMD）是聚集信息素的唯一成分，但DMD的行为活性很低。在本研究中，测试了另外两个先前报道的次生代谢产物（苯醌和碳氢化合物）的两种化学特性（EAG）。两个苯醌和三个单烯烃引起雄性和雌性触角均具有显着的EAG活性。对于三种烃中的两种以及两种醌，男性的EAG反应（相对于女性）均升高。随后在步行生物测定中研究了EAG活性化合物的行为活性。苯醌被认为是有毒的，并且已被指定为面粉甲虫的警报物质，但我们发现中等浓度的甲基-1，4-苯醌对雄性和雌性甲虫都有吸引力，因此可以充当聚集信息素成分。雄性也被吸引到乙基1,4-苯醌。相应的对苯二酚（假定为苯醌的前体）没有引起任何电生理反应，也没有进行行为活性测试。不饱和烃（1-十四碳烯，1-十
• CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE
  申请人：Lampe W. John

  公开号：US20080076735A1

  公开（公告）日：2008-03-27

  The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

  本发明涉及合成的细胞骨架活性化合物，其与天然拉曲林A或拉曲林B相关。本发明还涉及包含这种化合物和药学上可接受的载体的制药组合物。此外，本发明还涉及一种预防或治疗与肌动蛋白聚合有关的疾病或病症的方法。在本发明的一种实施例中，该方法治疗增加的眼内压，如原发性开角型青光眼。该方法包括向受试者给予公式I或II的细胞骨架活性化合物的治疗有效量，其中该量对细胞骨架产生影响，例如通过抑制肌动蛋白聚合。
• VIVO DETECTION OF PHOSPHOLIPASE ACTIVATION
  申请人：Delikatny E.J

  公开号：US20110165084A1

  公开（公告）日：2011-07-07

  The present invention is directed to a phospholipid-based NIR molecular beacon, having a phospholipid moiety; with an NIR fluorophore moiety covalently linked to a phospholipid glycerol backbone and a quencher moiety covalently linked to the phospholipid glycerol backbone. Additionally, provided herein is methods of analyzing a sample for the presence of a phospholipase and methods of identifying the activity of a phospholipase in vivo utilizing phospholipid-based NIR molecular beacon.